Binge Eating Medication Found Effective as Maintenance Therapy

This study was supported by Shire Development LLC, manufacturer of lisdexamfetamine (Vyvanase).To read more about this topic, see thePsychiatric News articles “FDA Approves First Drug for Binge-Eating Disorder” and “New DSM Guide Describes Changes to Eating, Elimination, Sleep Disorders Criteria. ”mgtrott/iStockWant to Learn About Reimbursement for Psychiatric Collaborative Care Services?APA is presenting a free webinar on Thursday, July 13, from noon to 1 p.m. that explains how to get paid for collaborative care services. This past January, the Centers for Medicare and Medicaid Services authorized payment for these services using HCPCS codes that describe the work of this model of care. Join the webinar and learn more about the billing and documentation requirements associated with the new codes.Register now!APA is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide CME for physicians. APA designates this live activity for a maximum of 1 AMA PRA Category 1 Credit.For previous news alerts,click here.
Source: Psychiatr News - Category: Psychiatry Tags: binge eating disorder lisdexamfetamine maintenance therapy relapse Vyvanase Source Type: research